Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

Targeting the TGFβ signalling pathway in disease

Abstract

Key PointsTransforming growth factor-β (TGFβ) has pleiotropic effects on many cell types in vivo, mediated via multiple signalling pathways — canonical and non-canonicalTGFβ signalling is modulated by other signalling pathways (for example, Notch and RAS).TGFβ effects are context-dependent: they are influenced by cell type, growth or differentiation status, and innate genetic variation.TGFβ is potently immune-modulatory and signalling is upregulated in, and can exacerbate, many disease states, especially cancer and fibrosis.Drugs for TGFβ signalling blockade have been developed that target biosynthesis, activation, ligand and receptor binding as well as downstream responses to TGFβ.Drug classes include antisense oligonucleotides (ASOs), ligand traps, antibodies, small-molecule chemical inhibitors, antisense genes, pyrrole-imidazole polyamide DNA binders and gene therapy.In cancer therapy, TGFβ blockade may suppress metastasis by targeting tumour-initiating cells, enhancing immune surveillance and cytotoxic T cell activity, modulating the tumour stroma and suppressing angiogenesis.In fibrosis, TGFβ blockade suppresses epithelial–mesenchymal transition, inhibits myofibroblast differentiation and proliferation, and prevents excessive elaboration of the extracellular matrix.Clinical trials are ongoing for applications in oncology and fibrosis.In oncology, clinical trials show promise with ASOs for malignant glioblastoma and pancreatic cancer, antibodies for metastatic melanoma and renal cell carcinoma, and chemical inhibition for glioblastoma, as well as augmentation of tumour vaccines for non-small-cell lung cancer.In fibrosis, clinical trials show promise for focal segmental glomerulosclerosis and diabetic kidney disease using anti-ligand antibodies, for scleroderma/skin fibrosis using a topical betaglycan mimetic peptide, and for idiopathic pulmonary fibrosis, glomerulosclerosis and diabetic kidney disease with pirfenidone.Combination therapies of chemotherapy or radiation with TGFβ blockade show great promise for oncology.Patient selection will be critical to obtain therapeutic efficacy and minimize side effects.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.